

# Global Peptide Therapeutics Pipeline Insight 2015

<https://marketpublishers.com/r/G148DA574EEEN.html>

Date: February 2015

Pages: 1200

Price: US\$ 2,400.00 (Single User License)

ID: G148DA574EEEN

## Abstracts

**Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.**

Peptides are small molecules of varying molecular masses that consist of amino acids joined with the help of peptide bonds (CONH<sub>2</sub>). One end of the molecule consists of carboxyl (COOH<sub>2</sub>) group while the other end has amino (NH<sub>2</sub>) group giving rise to polarity. Biologically, they are very important and found to play an important role in various anabolic and catabolic processes. They are essential component of cell signaling pathways, immune system, hormonal systems, enzymatic systems and others important systems in the body. Owing to same building blocks, sometimes they are confused with the proteins which are more or less biochemically similar in nature. Technically, peptide consists of upto 50 amino acids in the chain while proteins are much longer chains of amino acids.

Researchers have identified several peptides which are necessary part of body systems that could be used for pharmacological purposes during disease incidence. Peptides could be easily designed and modified according to necessity due to which they have high safety and efficacy profile. They are small in size due to which they can easily enter inside the cell and interact with desired molecules. They have low immunotoxicity due to which they have high tolerability and could be administered to patient of all age group. Various routes of delivery could be observed in this category; they could be injected or orally administrated to patients and newer methods like inhalation is presently under investigation. High bioavailability makes them highly potent as they are highly absorbable due to which lesser amount of therapeutics is required.

Use of peptides in several disease indications has been already proved by investigators and several of them are already available in market. Rapid introduction in market has become possible due to development of high yielding SPPS and LPPS methods. Both have same function of peptide synthesis but they differ in biochemistry due to which

their commercial utilization severely depends upon quantity, molecular weight, length of peptide and cost arbitrage. Purification costs also vary from process to process due which it becomes imperative to have effective method that can save time and money. Industrial biotechnologists are working with different modalities to develop new methods having fewer investments per unit peptide therapeutics produced per batch.

Peptide based therapeutics have highly diverse market with numerous categories that could be further divided into several sub categories. They have high market penetration rates across the globe and generate significant amount of revenues. Burgeoning pressure on pharmaceutical companies to come forth with highly effective therapeutic products along with higher cost arbitrage is driving the peptide based therapeutics market. Strong clinical pipeline allows the pharmaceutical companies to regularly introduce their products in global market. Both extreme ends could be observed in this segment reflecting divergence and interest of pharmaceutical companies. Some categories like insulin are quite mature while peptide cancer vaccine market segment is still emerging and has to pass through various phases of industry life cycle.

Peptide Segment Covered In Report:

Cyclic-Peptide, Polypeptide, Glycopeptide, Oligopeptide, Depsipeptide, Neuropeptide, Dipeptides, Natriuretic Peptide, Lipopeptide, Opioid Peptide, Peptide Vaccine, Antimicrobial Cationic Peptide & Insulin

“Global Peptide Therapeutics Pipeline Insight 2015” Report Highlights:

Global Peptide Therapeutics Market Overview

Global Peptide Therapeutics Pipeline By Peptide Type

Global Peptide Therapeutics Pipeline By Company, Indication & Phase

Peptide Therapeutics Clinical Pipeline: 743 Peptides

Majority Peptide Therapeutics in Preclinical Phase: 293 Peptides

Commercially available Peptides: 126 Peptides

## Contents

### **1. INTRODUCTION TO PEPTIDES**

### **2. MECHANISM OF PEPTIDE THERAPEUTICS**

### **3. GLOBAL PEPTIDE THERAPEUTICS MARKET OVERVIEW**

#### 3.1 Current Market Scenario

#### 3.2 Peptide Pipeline Overview

### **4. GLOBAL PEPTIDE THERAPEUTICS MARKET DYNAMICS**

#### 4.1 Market Growth Drivers

#### 4.2 Commercialization Challenges

### **5. GLOBAL PEPTIDE THERAPEUTICS MARKET FUTURE PROSPECTS**

### **6. INSULIN PIPELINE BY COMPANY, INDICATION & PHASE**

#### 6.1 Phase Research to till Registered

#### 6.2 Marketed

### **7. PEPTIDES PIPELINE BY COMPANY, INDICATION & PHASE**

#### 7.1 Phase Research to till Registered

#### 7.2 Marketed

### **8. CYCLIC PEPTIDES PIPELINE BY COMPANY, INDICATION & PHASE**

#### 8.1 Phase Research to till Preregistration

#### 8.2 Marketed

### **9. POLYPEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE**

#### 9.1 Phase Research to till Phase-III

#### 9.2 Marketed

## **10. GLYCOPEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE**

- 10.1 Phase Research to till Registered
- 10.2 Marketed

## **11. LIPOPEPTIDES PIPELINE BY COMPANY, INDICATION & PHASE**

- 11.1 Phase Research to till Phase-III
- 11.2 Phase: Marketed

## **12. OLIGOPEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE**

- 12.1 Phase Research to till Preregistration
- 12.2 Marketed

## **13. DEPSI PEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE**

- 13.1 Phase Research to till Phase-III
- 13.2 Marketed

## **14. NEUROPEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE**

- 14.1 Phase Preclinical to till Phase-II/III
- 14.2 Marketed

## **15. DIPEPTIDES PIPELINE BY COMPANY, INDICATION & PHASE**

- 15.1 Phase Preclinical to till Phase-III
- 15.2 Marketed

## **16. NATRIURETIC PEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE**

- 16.1 Phase Preclinical to till Phase-III

## **17. OPIOID PEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE**

- 17.1 Phase Preclinical to till Preregistration
- 17.2 Marketed

## **18. PEPTIDE VACCINE PIPELINE BY COMPANY, INDICATION & PHASE**

18.1 Phase Preclinical to till Phase-III

## **19. ANTIMICROBIAL CATIONIC PEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE**

19.1 Phase Preclinical to till Phase-III

## **20. MULTIPLE PEPTIDES PIPELINE BY COMPANY, INDICATION & PHASE**

20.1 Phase Preclinical to till Registered

20.2 Marketed

## **21. COMPETITIVE LANDSCAPE**

21.1 Amgen

21.2 Amylin Pharmaceuticals

21.3 Corden Pharma (Peptisyntha)

21.4 GlaxoSmithKline

21.5 Ipsen

21.6 Lonza

21.7 Merck

21.8 PeptiDream

21.9 Roche

21.10 Sanofi

## List Of Figures

### LIST OF FIGURES

- Figure 1-1: Components of Peptide
- Figure 1-2: Features of Peptide Therapeutics
- Figure 2-1: Benefits of Peptide Modifications
- Figure 2-2: Benefits of Computational Methods
- Figure 2-3: Different Types of Peptide Formulation Vehicles
- Figure 2-4: Mechanism of Vibativ
- Figure 2-5: Mechanism of Liraglutide
- Figure 2-6: Mechanism of Goserelin
- Figure 2-7: Formulation of Orally Administrated Peptide Therapeutics
- Figure 3-1: Global Peptide Market (US\$ Billion), 2013-2018
- Figure 3-2: Insulin Pipeline by Phase (%), 2015
- Figure 3-3: Insulin Pipeline by Phase (Number), 2015
- Figure 3-4: Peptides Pipeline by Phase (%), 2015
- Figure 3-5: Peptides Pipeline by Phase (Number), 2015
- Figure 3-6: Cyclic Peptide Pipeline by Phase (%), 2015
- Figure 3-7: Cyclic Peptide Pipeline by Phase (Number), 2015
- Figure 3-8: Polypeptide Pipeline by Phase (%), 2015
- Figure 3-9: Polypeptide Pipeline by Phase (Number), 2015
- Figure 3-10: Glycopeptide Pipeline by Phase (%), 2015
- Figure 3-11: Glycopeptide Pipeline by Phase (Number), 2015
- Figure 3-12: Lipopeptide Pipeline by Phase (%), 2015
- Figure 3-13: Lipopeptide Pipeline by Phase (Number), 2014
- Figure 3-14: Oligopeptide Pipeline by Phase (%), 2015
- Figure 3-15: Oligopeptide Pipeline by Phase (Number), 2015
- Figure 3-16: Depsi Peptide Pipeline by Phase (%), 2015
- Figure 3-17: Depsi Peptide Pipeline by Phase (Number), 2015
- Figure 3-18: Neuropeptide Pipeline by Phase (%), 2015
- Figure 3-19: Neuropeptide Pipeline by Phase (Number), 2015
- Figure 3-20: Dipeptide Pipeline by Phase (%), 2015
- Figure 3-21: Dipeptide Pipeline by Phase (Number), 2015
- Figure 3-22: Natriuretic Peptide Pipeline by Phase (%), 2015
- Figure 3-23: Natriuretic Peptide Pipeline by Phase (Number), 2015
- Figure 3-24: Opioid Peptide Pipeline by Phase (%), 2015
- Figure 3-25: Opioid Peptide Pipeline by Phase (Number), 2015
- Figure 3-26: Peptide Vaccine Pipeline by Phase (%), 2015

Figure 3-27: Peptide Vaccine Pipeline by Phase (Number), 2015

Figure 3-28: Antimicrobial-Cationic-Peptide Pipeline by Phase (%), 2015

Figure 3-29: Antimicrobial-Cationic-Peptide Pipeline by Phase (Number), 2015

Figure 3-30: Multiple Peptide Pipeline by Phase (%), 2015

Figure 3-31: Multiple Peptide Pipeline by Phase (Number), 2015

Figure 4-1: Global Peptide Therapeutics Market Growth Drivers

Figure 4-2: Global Peptide Therapeutics Market Commercialization Challenges

## I would like to order

Product name: Global Peptide Therapeutics Pipeline Insight 2015

Product link: <https://marketpublishers.com/r/G148DA574EEEN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G148DA574EEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970